Autoimmune antibodies can ravage the body – or not: Many individuals have measurable autoantibodies for years before the onset of clinical symptoms, and even once clinical disease is present, antibody titers do not correlate with disease severity. Read More
Cognition Therapeutics Inc., of Pittsburgh, said the first Alzheimer’s patient was dosed in a phase Ib trial of CT1812, an orally available, small molecule that displaces bound amyloid beta oligomers and inhibits binding of amyloid beta oligomers to the receptor complex, in mild to moderate Alzheimer’s disease. Read More
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said pursuant to a global alliance inked in January 2014, Paris-based Sanofi SA’s Genzyme unit elected to opt in to co-develop and co-commercialize fitusiran, an RNAi therapeutic for the treatment of hemophilia and rare bleeding disorders (RBD), in the U.S., Canada and Western Europe. Read More
SHANGHAI – Leaving politics aside, a Taiwanese company and a China counterpart plan to set up a $102 million joint venture to develop a dual drug, oral direct-acting antiviral treatment for chronic hepatitis C virus (HCV).
Read More
LONDON – The uncertainty generated by Brexit is having an impact on recruitment at the EMA and threatens to reduce its access to U.K. experts, who currently make a disproportionately large contribution to the work of the agency, according to its executive director, Guido Rasi.
Read More
After encouraging word from Europe, PTC Therapeutics Inc.’s “first strategy is to continue to try and push forward [in FDA discussions] with the data that we’ve got,” Chief Financial Officer Shane Kovacs told BioWorld Today. “Why should the kids wait another three years?”
Read More
What a turn of events! Now that Donald Trump has been given the keys to the White House following what turned out to be a close presidential election race – combined with the return of another Republican-controlled congress – the results of the presidential race have turned out to be a much needed tonic for an ailing biopharmaceutical sector that was expecting a much different outcome in Washington last week.
Read More
